Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1 + immune cells in Epstein-Barr virus-associated gastric cancer: The prognostic implications

Modern Pathology

Volumn 30, Issue 3, 2017, Pages 427-439

  Saito, Ruri ^a   Abe, Hiroyuki ^b   Kunita, Akiko ^a   Yamashita, Hiroharu ^a   Seto, Yasuyuki ^a   Fukayama, Masashi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CLONAL EVOLUTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SPECIFIC SURVIVAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRIC CANCER CELL LINE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER; STROMA CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; VERY ELDERLY; DISEASE EXACERBATION; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; VIROLOGY;

AGED; B7-H1 ANTIGEN; DISEASE PROGRESSION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85004045068     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.202     Document Type: Article

References (48)

1. Bosman FT, Carneiro F, Hruban RH et al. WHO Classification of Tumours of the Digestive System, 4th edn. IARC Press: Lyon, France, 2010.
2. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209.
3. Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014;46:573-582.
4. Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer [review]. Int J Oncol 2015;46:1421-1434.
5. Abe H, Kaneda A, Fukayama M. Epstein-Barr virusassociated gastric carcinoma: use of host cell machineries and somatic gene mutations. Pathobiology 2015;82:212-223.
6. Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci 2008;99:1726-1733.
7. Song HJ, Srivastava A, Lee J, et al. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 2010;139:84-92.
8. Hino R, Uozaki H, Murakami N, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009;69: 2766-2774.
9. Matsusaka K, Kaneda A, Nagae G, et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 2011;71:7187-7197.
10. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immuno-therapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99: 12293-12297.
11. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005;54:307-314.
12. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-242.
13. Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015;21: 24-33.
14. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
15. Szno M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021-1034.
16. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-1766.
17. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-116.
18. Zhang Lin, Miaozhen Qiu, Ying Jin, et al. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol 2015;8:11084-11091.
19. Qing Y, Li Q, Ren T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther 2015;9:901-909.
20. Kim JW, Nam KH, Ahn SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 2016;19:42-52.
21. Thompson ED, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut; available from: URL: http://gut. bmj. com/content/early/ 2016/01/22/gutjnl-2015-310839. long.
22. Liu YX, Wang XS, Wang YF, et al. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: A meta-analysis. Onco Targets Ther 2016;9:2649-2654.
23. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-404.
24. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal; available from: URL: http://stke. sciencemag. org/content/sigtrans/6/269/pl1. full. pdf.
25. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
26. Abe H, Morikawa T, Saito R, et al. CD66b-positive tumor-associated neutrophils in Epstein-Barr virus associated gastric carcinoma. A comparative study with CD8-positive cytotoxic T-lymphocytes. Virchows Arch 2016;468:539-548.
27. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-Cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013;19:3462-3473.
28. Fang W, Zhang J, Hong S, et al. EBV-driven LMP1 and IFN-up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014;5:12189-12202.
29. Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013;1: 54-63.
30. Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009;23:375-382.
31. Derks S, Liao X, Chiaravalli AM, et al. Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget 2016;7:32925-32932.
32. Boger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016;7: 24269-24283.
33. Li Z, Lai Y, Sun L, et al. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol 2016;55: 182-189.
34. Inaguma S, Wang Z, Lasota J, et al. Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): Analysis in 5536 cases revealed consistent expression in trophoblastic tumors. Am J Surg Pathol 2016;40:1133-1142.
35. Grogg KL, Lohse CM, Pankratz VS, et al. Lymphocyterich gastric cancer: Associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003;16:641-651.
36. Chen J, Jiang CC, Jin L, et al. Regulation of pd-l1: A novel role of pro-survival signalling in cancer. Ann Oncol 2016;27:409-416.
37. Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 2016;534:402-406.
38. Shinozaki A, Sakatani T, Ushiku T, et al. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res 2010;70:4719-4727.
39. Hino R, Uozaki H, Inoue Y, et al. Survival advantage of EBV-associated gastric carcinoma: survivin upregulation by viral latent membrane protein 2A. Cancer Res 2008;68:1427-1435.
40. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116.
41. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-571.
42. Taylor GS, Steven NM. Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. Chin Clin Oncol 2016;5:23.
43. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717-726.
44. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387: 1837-1846.
45. Smith J, Robida MD, Acosta K, et al. Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N. Diagn Pathol 2016; 11:44.
46. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art J Thorac Oncol 2015;10: 985-989.
47. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2016;2:46-54.
48. Ye P, Zhang M, Fan S, et al. Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: Optimizing personalized healthcare through innovative pathological and statistical analysis. PLoS One 2015;10:e0143207.